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Purpose: In numerous clinical and experimental studies, preservatives present in eye drops have had detrimental effects
on ocular epithelial cells. The aim of this study was to compare the cytotoxic and inflammatory effects of the preservative
polyquaternium-1 (PQ-1) containing Travatan (travoprost 0.004%) and Systane Ultra eye drops with benzalkonium
chloride (BAK) alone or BAK-preserved Xalatan (0.005% latanoprost) eye drops in HCE-2 human corneal epithelial cell
culture.
Methods: HCE-2 cells were exposed to the commercial eye drops Travatan, Systane Ultra, Xalatan, and the preservative
BAK.  Cell  viability  was  determined  using  colorimetric  MTT  (3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay and by release of lactate dehydrogenase (LDH). Induction of apoptosis was measured with a using a
colorimetric caspase-3 assay kit. DNA binding of the nuclear factor kappa B (NF-κB) transcription factor, and productions
of the proinflammatory cytokines, interleukins IL-6 and IL-8, were determined using an enzyme-linked immunosorbent
assay (ELISA) method.
Results: Cell viability, as measured by the MTT assay, declined by up to 50% after exposure to Travatan or Systane Ultra
solutions which contain 0.001% PQ-1. BAK at 0.02% rather than at 0.001% concentration evoked total cell death signs
on HCE-2 cells. In addition, cell membrane permeability, as measured by LDH release, was elevated by sixfold with
Travatan and by a maximum threefold with Systane Ultra. Interestingly, Travatan and Systane Ultra activated NF-κB and
elevated the secretion of inflammation markers IL-6 by 3 to eightfold and IL-8 by 1.5 to 3.5 fold, respectively, as analyzed
with ELISA.
Conclusions: Eye drops containing PQ-1 evoke cytotoxicity and enhance the NF-κB driven inflammation reaction in
cultured HCE-2 cells. Our results indicate that these harmful effects of ocular solutions preserved with PQ-1 should be
further evaluated in vitro and in vivo.
Benzalkonium chloride (BAK) is the most commonly
used preservative in ophthalmic drops. BAK has cytotoxic
effects and it has been shown to induce inflammation on the
ocular surface cells in numerous in vitro and in vivo models
[1-11]. Since the clinical treatment of glaucoma or dry eye
syndrome usually requires a long-term topical drug therapy,
ocular side effects may be potentiated by the use of preserved
ocular  drops  [4,6,7,12].  Polyquaternium-1  0.001%
(Polyquad®, PQ-1) is a detergent-type preservative derived
from BAK. PQ-1 was formulated in the mid of 1980s by Alcon
as a preservative for contact lens storage solutions. Nowadays,
it is being increasingly used as a preservative in ophthalmic
drops  for  glaucoma  and  artificial  tear  solutions.  Recent
findings  reveal  that  PQ-1  has  detrimental  effects  on  cell
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membrane  integrity  and  it  induces  cytotoxicity  in  ocular
surface cells [13,14]. Cell membrane damage may activate
inflammation and cytotoxicity via Toll-like receptors (TLRs)
that are a class of proteins playing a key role in the innate
immune system [15]. TLRs are classical inducers of nuclear
factor  kappa  B  (NF-κB)  transcription  factor  that  is  a
ubiquitous  inducible  transcription  factor,  and  the  master
regulator of acute and chronic immune responses, cellular
proliferation and cell death. The NF-κB protein complex is
maintained  in  the  cytoplasm  in  an  inactive  state  by  the
presence of inhibitory kappa proteins (IκBs). In response to
various stress stimuli, IκB kinase (IKK) can phosphorylate
IκB proteins which, in turn, leads to NF-κB activation through
the formation of a heterodimer of p50 and p65 NF-κB subunits
which is then translocated to the nucleus where it triggers the
activation of many inflammatory genes, such as interleukins
IL-6 and IL-8 [15].
This study explored the hypothesis that PQ-1 might have
some detrimental effects on ocular surface cells. Therefore,
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1189cytotoxicity,  cellular  permeability  and  the  inflammatory
effects of commercial eye drops containing PQ-1 0.001%
(Travatan and Systane Ultra) or an eye drop with BAK 0.02%
(Xalatan) and pure BAK 0.001% or 0.02% were analyzed
using HCE-2 human corneal epithelial cell cultures.
METHODS
Cell culturing and treatments: Cells used in this study were
human  corneal  epithelial  cells  (HCE-2)  obtained  from
American Type Culture Collection (ATCC, Manassas, VA).
The  cells  were  grown  to  confluency  on  12-well  plates
(Cellstar®; Greiner Bio-One GmbH, Frickenhausen Germany)
in a standard cell culture incubator (humidified CO2 10%
athmosphere and 37 °C). Keratinocyte- Serum Free Medium
(SFM, with bovine pituitary extract and epidermal growth
factor, cat. no. 17005–042; Life Technologies, Invitrogen,
GIBCO®, Paisley, UK) containing insulin 0.005 mg/ml (cat.
no.  I-6634;  Sigma-Aldrich,  Steinheim,  Germany),  fetal
bovine  serum  10%  (FBS,  cat.  no.  CH30160.03;  Thermo
Scientific, Hyclone, Logan, UT) and penicillin 100U/ml +
streptomycin 100 µg/ml (cat. no. DE17–602E; Lonza, Basel,
Switzerland) was used as the culture medium. Fresh medium
was supplied to the cells every other day and the cells were
subcultured twice a week using 0.25% trypsin-EDTA (cat. no.
25200056; Life Technologies, Invitrogen) to detach the cells
from plates.
The cells were exposed to the treatments (see below) for
5, 15, and 30 min, and then kept in the cell culture medium
for 24 h, except for NF-κB activity test for 6 h, on 12 well
plates before being analyzed. For every well 100,000 cells
were seeded and cultured for 48 h before of exposures. Culture
medium volume was 1 ml per dish, while for exposures used
volume was 0.5 ml per dish. The cells were washed once with
keratinocyte-SFM medium (without any supplements) before
and after treatment to prevent any extra protein precipitation
caused by BAK. The treatments were: 0-control (normal cell
culture  medium),  Travatan  (40  µg/ml  travoprost,
polyquaternium-1/polidronium  chloride  0.001%  as
preservative; Alcon, Hünenberg, Switzerland), Systane Ultra
(artificial tear drops, Polyquaternium-1/polidronium chloride
0.001% as preservative; Alcon), BAK 0.001% and 0.02% v/
v aqueous solution (FeF Chemicals A/S, Køge, Denmark), and
Xalatan (0.005% latanoprost, BAK 0.02% as preservative;
Pfizer, New York City, NY).
Cell viability:
MTT  assay—The  cytotoxicity  of  exposure  was
measured with MTT-assay [16]. Color of MTT tetrazole salt
was measured with a spectrophotometer at the wavelength of
570 nm. Briefly, fresh MTT solution (10 mg/ml in 1× PBS)
was  added  (1:20  volume  of  medium)  and  the  cells  were
incubated for 1.5 h. The cells were lysed and purple formazan
dissolved into the solution by overnight incubation with MTT-
lysis buffer (20% SDS, 50% N,N-dimethylformamide, 2%
acetic acid, 25mM HCl; the volume of medium + volume of
MTT-salt solution).
LDH assay—The permeability of cellular membranes
following the exposures was determined by measuring the
amount  of  released  lactate  dehydrogenase  (LDH)  enzyme
from HCE-2 cells. The commercial CytoTox 96® -kit (cat.
no. G1780; Promega, Fitchburg, WI) was used according to
the manufacturer’s instructions. Maximum LDH release of
HCE-2 cells was determined by lysing HCE-2 cells for 45 min
(lysis buffer provided within the assay), and subsequently
measuring the LDH from the culture medium. Absorbance
values after the colorimetric reaction were measured at the
wavelength of 490 nm with a reference wavelength of 655 a
BIO-RAD  Model  550  microplate  reader  (BIO-RAD,
Hercules, CA).
Caspase-3—The levels of an apoptosis marker caspase-3
(active  form)  were  measured  from  cell  lysates  using  a
colorimetric assay kit (cat. no. CASP-3-C; Sigma-Aldrich).
Caspase-3 hydrolyses the peptide substrate Ac-DEVD-pNA
(acetyl-Asp-Glu-Val-Asp p-nitroanilide) releasing pNA (p-
nitroaniline) which can be measured at the wavelength of 405
nm. The assay was performed according to the instructions of
the manufacturer. Caspase-3 (Product Code C5974; Sigma)
was used as a positive control, and the Assay Buffer provided
with  the  kit  served  as  a  negative  control.The  absorbance
values  were  measured  using  a  BIO-RAD  Model  550
microplate reader (BIO-RAD).
Inflammation:
IL-6 and IL-8 assays—The concentrations (pg/ml) of
IL-6 were measured from cell culture medium samples in
duplicates by BD OptEIA™ Human IL-6 ELISA Set (cat. no.
555220; BD Biosciences, San Diego, CA). The assay was
performed according to the instructions of manufacturer. For
determining  the  IL-8  concentrations  (pg/ml),  the  BD
OptEIA™  Human  IL-8  ELISA  Set  (cat.  no.  555244;  BD
Biosciences)  was  used.  The  absorbance  values  after  the
colorimetric reaction were measured at the wavelength of 450
nm with a reference wavelength of 655 nm using a BIO-RAD
Model 550 microplate reader (BIO-RAD).
NF-κB assay—NF-κB p65 ELISA kit (cat. no. EKS-446)
was obtained from Enzo Life Sciences (Lausen, Switzerland)
and used to measure p65 subunit after the binding to DNA.
The cells were lysed in 25% glycerol, 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 20 mM HEPES before analyses, and
the  assay  was  performed  according  to  the  manufacturer’s
instructions using 10 μg of protein per well. The luminescence
signal  was  measured  using  VICTOR™  1420  multilabel
counter (PerkinElmer/Wallac, Turku, Finland).
Statistical analysis: Statistical analyses were conducted with
GraphPad  Prism  (Graphpad  Software,  San  Diego,  CA).
Differences between groups were analyzed with the one-way
ANOVA test followed by Dunnett’s post hoc tests. P-values
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1190below  0.05  were  considered  significant.  There  were  six
parallel samples in every analysis.
RESULTS
Cellular  viability:  MTT  analysis  revealed  the  extensive
toxicity associated with BAK 0.02% containing Xalatan and
BAK 0.02% (Figure 1). Both solutions evoked total cell death
even after 5 min of exposure (followed by 24 h recovery in
normal medium). At the same time point, the viability of cells
exposed to Travatan, Systane Ultra and BAK 0.001% was near
to the control. At later time points (15 and 30 min exposure +
24 h recovery) Travatan, Systane Ultra, and BAK 0.001%
exposures  reduced  cellular  viability  in  a  time  dependent
manner. Based on the MTT analysis results and the extensive
protein precipitation caused by the higher concentration of
BAK (0.02%) and Xalatan, they were excluded from further
experiments.
Cellular permeability analysis, measured via the release
of LDH, indicated that exposure to Travatan (preserved with
PQ-1) was the most harmful (Figure 2). After 5 min exposure
(followed by 24 h recovery in normal medium) the mortality
was approx. 25%, which increased at later time points (15 and
30  min)  up  to  50%.  In  addition  Systane  Ultra  and  BAK
(0.001%) were slightly toxic to HCE-2 cells as reflected in the
decline  in  cellular  viability  from  10%  to  20%.  However,
Systane Ultra seemed to be slightly more toxic at the 30 min
time point.
Caspase-3 levels were elevated after 5 min of exposure
to Travatan (followed by 24 h recovery in normal medium)
when compared to control cells (Figure 3). Moreover, the
Figure 1. Level of cytotoxicity in HCE-2 cells analyzed by MTT assay. Columns represent the viability of cells (mean±SD. The viability of
control cells is set as 100%. One-Way ANOVA, followed by Dunnett’s post hoc test, evaluated the statistical differences (n=6, *0.01<p≤0.05,
**0.001<p≤0.01, ***p≤0.001, ns=not significant). Experiments were repeated three times.
Figure 2. Released amount of lactate dehydrogenase (LDH) from HCE-2 cells. Columns represent the mortality (mean±SD) of cells, total
cellular death being 100%. One-Way ANOVA, followed by Dunnett’s post hoc test, evaluated the statistical differences (n=6, *0.01<p≤0.05,
**0.001<p≤0.01, ***p≤0.001, ns=not significant). Experiments were repeated three times.
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1191exposure for 15 and 30 min to Travatan and Systane Ultra
solutions  increased  the  level  of  caspase-3,  although  the
increase was not statistically significant.
Inflammation:  Travatan,  Systane  Ultra  and  BAK  0.001%
increased IL-6 levels already after a 5 min exposure when
compared to the controls (Figure 4). There was approximately
three times more IL-6 released into the culture medium of the
Travatan and Systane Ultra-treated cells. After 15 min of
exposure to Travatan and Systane Ultra, the levels were 8
times higher than the controls. For comparison, BAK 0.001%
increased  the  amount  of  IL-6  by  only  about  twofold  in
response to 15 min´ treatment. The 30 min exposure amplified
the levels even more in Systane Ultra (~10×) and in BAK
0.001%-treated (~4×) samples, whereas in Travatan exposed
samples  the  IL-6  levels  were  the  same  as  in  the  15  min
samples. The response of interleukin-8 was similar to that seen
with IL-6 (Figure 5), although the elevations were not as
dramatic (with Travatan ~50%–300%, Systane Ultra ~0%–
350% and no elevation with BAK 0.001%). NF-κB levels
were increased statistically significantly in the Systane Ultra
(15 and 30 min exposures) and Travatan (30 min exposure)
treated cells (Figure 6). BAK 0.001% did not have any effect
on the NF-κB expression.
DISCUSSION
The ocular toxicity associated with BAK has been known for
decades [17]. Preservative-free ophthalmic compounds are
safer and better tolerated than BAK-preserved solutions [18],
Figure 3. Active caspase-3 analysis in HCE-2 cells. Columns represent the proportion of caspase-3 from positive control which was set to be
100% (mean±SD). One-Way ANOVA, followed by Dunnett’s post hoc test, evaluated the statistical differences (n=6, *0.01<p≤0.05,
**0.001<p≤0.01, ***p≤0.001, ns=not significant). Experiments were repeated three times.
Figure 4. Interleukin-6 secretion from HCE-2 cells analyzed by ELISA. Columns represent the amount of IL-6 pg/ml (mean±SD). One-Way
ANOVA, followed by Dunnett’s post hoc test, evaluated the statistical differences (n=6, *0.01<p≤0.05, **0.001<p≤0.01, ***p≤0.001, ns=not
significant). Experiments were repeated three times.
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1192but antimicrobial preservatives are required for the use of
multi-dosage medicine containers. New preservatives, such as
polyquaternium-1 (PQ-1), have been developed as alternative
to BAK [19]. PQ-1, a detergent-type preservative derived
from BAK, has been used in artificial tears since the 1980s,
and  recent  studies  have  assessed  its  suitability  as  a
preservative for prostaglandin analogs used in antiglaucoma
therapy [20]. The main disadvantage associated with PQ-1 is
its tendency to reduce the density of conjunctival goblet cells,
thereby decreasing the aqueous tear film production [21].
Despite being less toxic to the corneal surface than BAK, PQ-1
is known to induce damage to corneal epithelial cells as well
[22]. This is the first study to demonstrate that while PQ-1
induces cytotoxicity, it also induces inflammation in an NF-
kB-dependent manner in corneal epithelial cells.
Not only preservatives, drugs and excipients also may
evoke potential cytotoxicity [23]. Several in vitro studies have
shown  that  active  antiglaucoma  compounds  do  not  exert
cytotoxic effects [24,25]. On the contrary, recent studies have
reported  controversial  results  of  protective  effects  of
prostaglandin  analogs  against  BAK-induced  toxicity  in
human conjuctival cells [26-28]. The discrepancies in these
studies might be due to the different BAK concentrations used
as well as different cell line characteristics [22]. The drug
solutions containing PQ-1 as preservative as well as BAK
0,001% showed cytotoxicity in a time-dependent manner in
corneal epithelial cells, measured via the MTT assay, whereas
Figure 5. Interleukin-8 secretion from HCE-2 cells analyzed by ELISA. Columns represent the amount of IL-8 pg/ml (mean±SD).. One-Way
ANOVA, followed by Dunnett’s post hoc test, evaluated the statistical differences (n=6, *0.01<p≤0.05, **0.001<p≤0.01, ***p≤0.001, ns=not
significant). Experiments were repeated three times.
Figure 6. Binding of NF-κB (p65) to DNA 6 h after stimulation in HCE-2 cells. Columns represent the amount of NF-κB (mean±SD), control
is  set  as  100%.  One-Way  ANOVA,  followed  by  Dunnett’s  post  hoc  test,  evaluated  the  statistical  differences  (n=6,  *0.01<p≤0.05,
**0.001<p≤0.01, ***p≤0.001, ns=not significant). Experiments were repeated three times.
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1193the LDH assay revealed that exposure to Travatan (which
contains PQ-1) evoked the most prominent LDH release of
these  three  exposures  as  compared  non-treated  cells.  The
observed  LDH  increase  may  be  a  result  of  the  drug  i.e.,
travoprost, changing cell membrane integrity and function
[23]. However, it is important to notice that LDH release does
not always mean increased cytotoxicity, when analyzed by
sensitive ELISAs.
Our findings with human corneal epithelial cells are in
agreement  with  Brasnu  et  al.  [23]  who  reported  similar
toxicity in conjunctiva-derived epithelial cells after 15 min of
exposure to BAK 0.001%. However, in the present study it
was found that PQ-1 0.001% containing eye drops showed
similar or higher cytotoxic effects as BAK 0.001% after 15
min in cytotoxicity assays. The hypothesis of reduced cellular
toxicity of PQ-1 is based on its larger size (approximately 27
times  larger  than  BAK  molecule)  which  results  in  its
diminished capability of passing into the cornea [22,29]. In
addition, PQ-1 lacks the hydrophobic domain present in the
BAK molecule [22]. In earlier studies, the reduced cytotoxic
effects of PQ-1 in comparison to BAK were explained by the
latter’s corneal permeability [30]. Contrary to earlier results,
the results from our study suggest that PQ-1 exerts almost as
extensive cytotoxicity as BAK, in a time dependent manner
i.e., depending on the cytotoxicity assay being used.
In  vitro  study  does  not  mimic  precisely  the  in  vivo
conditions; in vivo tears may provide additional protection as
well as diminishing the direct contact time of cytotoxic agents
to corneal cells. However, it has been proposed that detergent-
type agents, such as BAK, can be absorbed into ocular tissues
i.e.,  they  can  exert  effects  long  after  contact  with  the
preservative  has  ceased  [27,28].  Low  concentrations
(0.001%) of BAK can induce growth arrest and apoptosis in
conjunctival cells in vitro for many hours after exposure to the
compound [31]. In addition, BAK has induced necrosis when
present at moderate concentrations, although apoptosis seems
to  be  triggered  low  detergent  concentrations  (0.0001%  to
0.001%) in a dose-dependent manner [31]. In a rabbit model
it was reported that the cell-permeable preservative BAK can
accumulate in the conjunctiva and cornea of the eye, and may
therefore continue to act long after the actual drug is no longer
present in tears [28,32]. It is not known whether PQ-1 exerts,
at least in part, the same prolonged effects. However, the
increase in caspase-3 activity induced by the PQ-1-containing
eye drops after 15 min incubation was also observed at the
other two time points although these increases did not reach
statistical significance. Interestingly, BAK 0.001% did not
affect the caspase-3 levels. The 5, 15, and 30 min incubations
used in our study may mimic the innate contact of corneal
exposure as well as in multi-treatment conditions, and these
exposure times are in concordance with the in vitro schedules
used in cytotoxic preservative corneal research.
The apoptosis and inflammation pathways are closely
linked  through  their  common  mediators  and  transduction
signals. It is a generally established dogma that apoptosis does
not  induce  inflammation  [33].  However,  some  pro-
inflammatory cytokines, such as tumor necrosis factor alpha
(TNF-α), interferon gamma (IFN- γ), and IL-1, can induce
apoptosis [34,35] while IL-6 and IL-8 have been shown to
inhibit apoptosis through several mechanisms [36,37]. The
rapid induction of IL-6 mRNA expression detected in corneal
tissues is evidence that IL-6 is closely involved in the host
corneal response during inflammatory conditions [38]. Our
findings revealed that Travatan and Systane Ultra (which both
have PQ-1) were able to induce the expression of IL-6 and
IL-8 but not IL-1beta (data not shown). BAK 0.001% slightly
increased  IL-6,  but  had  no  effect  on  the  IL-8  level.  We
observed  a  trend  toward  a  caspase-3  (apoptosis  marker)
increase  in  a  time-dependent  manner  with  Travatan  and
Systane Ultra. In addition, we found a statistically significant
NF-kB induction by eye drops containing PQ-1, indicating
that  the  increase  in  IL-6  and  IL-8  expression  was  being
mediated via NF-kB activation. These data suggest that PQ-1
induces  inflammatory  rather  than  caspase-3  -mediated
apoptosis in corneal epithelial cells and this mechanism is
associated with activation of NF-kB.
In  conclusion,  the  cationic  polymer  polyquad  (PQ-1
0.001%)  preservative  was  less  cytotoxic  in  vitro  than  the
highest commercial BAK (0.02%) concentrations. However,
PQ-1  containing  eye  drops  did  induce  even  stronger
inflammatory response than did BAK 0.001% exposure in
human corneal epithelial cells. Further studies will be needed
to elucidate the exact mechanism of this action, and whether
these effects occur also in vivo, especially in conjunction with
long-lasting therapy.
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